Needle-free diluent technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Needle-free diluent technology


Pharmaceutical Technology Europe

The Needle-Free diluent kit is a concept created by bioluz and Technoflex in response to the FDA and the UK’s National Health Service (NHS) publishing recommendations to prevent healthcare staff from needle-stick injuries during the reconstitution of intravenous (IV) drugs.

The kit consists of the active substance in a vial (lyophilized powder), a diluents bag and a sterile, blister‑packaged needle‑free device. Reconstituting the IV drug into a flexible bag is completed within a few steps.

Compared with traditional methods, this technology is easy to use, safe (needle-free), avoids mixing errors and saves time because all components are provided in the same package. Furthermore, as the vial is always attached to the bag, it is clear which active substance has been added in the bag and how much. Although this technology is more expensive than traditional methods, its benefits outweigh the cost, as evidenced by its popularity in the US; we expect a similar uptake in Europe. Eventually, we hope to improve this technology by supplying the kit pre-assembled.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
22%
Greater adoption of continuous manufacturing
7%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
35%
The rise of biologic-based drugs in commercial product portfolios and pipelines
30%
Greater adoption of the preferred provider model in outsourcing
7%
View Results
Jim MillerOutsourcing OutlookJim Miller Channeling Steve Jobs
Patricia Van ArnumIngredients InsiderPatricia Van ArnumSeeking Chemocatalytic and Biocatalytic Solutions
Nathan JessopIndustry InsiderNathan Jessop Taxing Times for French Pharma
Lynn D. TorbeckStatistical Solutions Lynn D. TorbeckRepresentative Sampling
Report on Recent and Upcoming Single-Use Meetings
ICH Q11 Reaches Harmonization, Implementation is Next
Digital Signatures Growing as a Result of Part 11
Single-Cell Genomics Advancing Molecular Biology
Putting FDA’s “Process Validation” Guidance into Action
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here